OWC, GC Group to develop new cannabinoid-based drugs
GC Group is an Israeli pharmaceutical R&D firm engaged in development of several new generic drug products of different types. As part of the deal, GC Group will
Daiichi Sankyo has entered a collaboration with France-based Waiv, which aims to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme.
The anti-cancer agent is designed to treat relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted